{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:49:51Z","timestamp":1784735391619,"version":"3.55.0"},"reference-count":138,"publisher":"Jaypee Brothers Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.59556\/japi.72.0573","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:03:54Z","timestamp":1752213834000},"page":"79-93","source":"Crossref","is-referenced-by-count":6,"title":["Responsible Use of Oral Corticosteroids in People with Comorbid Diabetes: An Expert Consensus"],"prefix":"10.59556","volume":"72","author":[{"given":"Banshi","family":"Saboo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij Mohan","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sreenivasamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minakshisundaram","family":"Shunmugavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagendra Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap","family":"Jethwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Swarnakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmy","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Qamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathy","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250711060345_B1","unstructured":"IDF Atlas, 10th edition. 2021 https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf"},{"issue":"(7):","key":"key20250711060345_B2","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(8):","key":"key20250711060345_B3","doi-asserted-by":"crossref","first-page":"e0181661.","DOI":"10.1371\/journal.pone.0181661","article-title":"Prevalence and pattern of co morbidity among type2 diabetics attending urban primary healthcare centers at Bhubaneswar (India).","volume":"12","author":"Pati","year":"2017;","journal-title":"PLoS One"},{"issue":"(4):","key":"key20250711060345_B4","doi-asserted-by":"crossref","first-page":"460\u2013","DOI":"10.1513\/AnnalsATS.201704-288OC","article-title":"Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis.","volume":"15","author":"Fern\u00e1ndez P\u00e9rez","year":"2018;","journal-title":"Ann Am Thorac Soc"},{"issue":"(12):","key":"key20250711060345_B5","first-page":"1131\u2013","article-title":"Clinical study of patients with idiopathic interstitial pneumonia accompanied by diabetes mellitus.","volume":"32","author":"Suga","year":"1994;","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"issue":"(1):","key":"key20250711060345_B6","doi-asserted-by":"crossref","first-page":"55\u2013","DOI":"10.2337\/dc09-0880","article-title":"Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer.","volume":"33","author":"Ehrlich","year":"2010;","journal-title":"Diabetes Care"},{"issue":"(8):","key":"key20250711060345_B7","doi-asserted-by":"crossref","first-page":"351\u2013","DOI":"10.4239\/wjd.v11.i8.351","article-title":"Interstitial lung disease and diabetes.","volume":"11","author":"Rajasurya","year":"2020;","journal-title":"World J Diabetes"},{"key":"key20250711060345_B8","doi-asserted-by":"crossref","first-page":"221.","DOI":"10.1186\/1471-2458-8-221","article-title":"Prevalence of comorbidity of chronic diseases in Australia.","volume":"8:","author":"Caughey","year":"2008;","journal-title":"BMC Public Health"},{"issue":"(5):","key":"key20250711060345_B9","doi-asserted-by":"crossref","first-page":"449\u2013","DOI":"10.2337\/diab.24.5.449","article-title":"Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell\u2019s palsy).","volume":"24","author":"Adour","year":"1975;","journal-title":"Diabetes"},{"issue":"(10):","key":"key20250711060345_B10","doi-asserted-by":"crossref","first-page":"3009\u2013","DOI":"10.2337\/dc12-2197","article-title":"Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications.","volume":"36","author":"Caughey","year":"2013;","journal-title":"Diabetes Care"},{"issue":"(4):","key":"key20250711060345_B11","doi-asserted-by":"crossref","first-page":"457\u2013","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids.","volume":"15","author":"Oray","year":"2016;","journal-title":"Expert Opin Drug Saf"},{"issue":"(2):","key":"key20250711060345_B12","doi-asserted-by":"crossref","first-page":"317\u2013","DOI":"10.2165\/00003495-199550020-00008","article-title":"Deflazacort. A review of its pharmacological properties and therapeutic efficacy.","volume":"50","author":"Markham","year":"1995;","journal-title":"Drugs"},{"issue":"(1):","key":"key20250711060345_B13","doi-asserted-by":"crossref","first-page":"38.","DOI":"10.1038\/s41533-019-0150-x","article-title":"Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study.","volume":"29","author":"Price","year":"2019;","journal-title":"NPJ Prim Care Respir Med"},{"issue":"(4):","key":"key20250711060345_B14","doi-asserted-by":"crossref","first-page":"335\u2013","DOI":"10.1016\/j.jdiacomp.2018.12.012","article-title":"Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy.","volume":"33","author":"Zylla","year":"2019;","journal-title":"J Diabetes Complications"},{"issue":"(8):","key":"key20250711060345_B15","doi-asserted-by":"crossref","first-page":"1073\u2013","DOI":"10.4239\/wjd.v6.i8.1073","article-title":"Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review.","volume":"6","author":"Tamez-P\u00e9rez","year":"2015;","journal-title":"World J Diabetes"},{"key":"key20250711060345_B16","doi-asserted-by":"crossref","first-page":"1577\u2013","DOI":"10.2147\/DMSO.S330253","article-title":"Management of glucocorticoid-induced hyperglycemia.","volume":"15:","author":"Shah","year":"2022;","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"(9):","key":"key20250711060345_B17","doi-asserted-by":"crossref","first-page":"717\u2013","DOI":"10.1046\/j.1525-1497.2002.10649.x","article-title":"Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly.","volume":"17","author":"Blackburn","year":"2002;","journal-title":"J Gen Intern Med"},{"key":"key20250711060345_B18","doi-asserted-by":"crossref","first-page":"203\u2013","DOI":"10.1016\/j.diabres.2018.03.006","article-title":"Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review.","volume":"139:","author":"Bonaventura","year":"2018;","journal-title":"Diabetes Res Clin Pract"},{"key":"key20250711060345_B19","doi-asserted-by":"crossref","first-page":"4\u2013","DOI":"10.4103\/ijem.ijem_227_21","article-title":"Diagnosis and management considerations in steroid-related hyperglycemia in COVID-19: a position statement from the endocrine society of India.","volume":"25:","author":"Das","year":"2021;","journal-title":"Indian J Endocr Metab"},{"issue":"(8):","key":"key20250711060345_B20","doi-asserted-by":"crossref","first-page":"1011\u2013","DOI":"10.1111\/dme.13675","article-title":"Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for inpatient care group.","volume":"35","author":"Roberts","year":"2018;","journal-title":"Diabet Med"},{"issue":"(5):","key":"key20250711060345_B21","doi-asserted-by":"crossref","first-page":"937\u2013","DOI":"10.1007\/s13300-023-01393-6","article-title":"Practical guide to glucocorticoid induced hyperglycaemia and diabetes.","volume":"14","author":"Barker","year":"2023;","journal-title":"Diabetes Ther"},{"key":"key20250711060345_B22","doi-asserted-by":"crossref","first-page":"80.","DOI":"10.1186\/s13098-020-00583-7","article-title":"Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes.","volume":"12:","author":"Alessi","year":"2020;","journal-title":"Diabetol Metab Syndr"},{"issue":"(7):","key":"key20250711060345_B23","doi-asserted-by":"crossref","first-page":"25.","DOI":"10.1007\/s11892-020-01307-x","article-title":"Euglycemic ketoacidosis.","volume":"20","author":"Bonora","year":"2020;","journal-title":"Curr Diab Rep"},{"issue":"(9):","key":"key20250711060345_B24","doi-asserted-by":"crossref","first-page":"540\u2013","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions.","volume":"18","author":"Li","year":"2022;","journal-title":"Nat Rev Endocrinol"},{"key":"key20250711060345_B25","author":"Gosmanov"},{"issue":"(4):","key":"key20250711060345_B26","doi-asserted-by":"crossref","first-page":"E708\u2013","DOI":"10.1152\/ajpendo.1999.277.4.E708","article-title":"Glucocorticoids reverse leptin effects on food intake and body fat in mice without increasing NPY mRNA.","volume":"277","author":"Solano","year":"1999;","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"key20250711060345_B27","unstructured":"https:\/\/bestpractice.bmj.com\/topics\/en-us\/162\/aetiology"},{"issue":"(4):","key":"key20250711060345_B28","doi-asserted-by":"crossref","first-page":"122\u2013","DOI":"10.4103\/0971-4065.34858","article-title":"Steroid induced diabetes mellitus presenting as diabetic ketoacidosis.","volume":"12","author":"Agarwal","year":"2002;","journal-title":"Indian J Nephrol"},{"issue":"(2):","key":"key20250711060345_B29","first-page":"131\u2013","article-title":"Steroid-induced diabetic ketoacidosis in a patient with type 2 diabetes mellitus.","volume":"4","author":"Tiwari","year":"2018;","journal-title":"AACE Clin Case Rep"},{"issue":"(5):","key":"key20250711060345_B30","doi-asserted-by":"crossref","first-page":"787.","DOI":"10.7326\/0003-4819-72-5-787_1","article-title":"Steroid-induced diabetic ketoacidosis.","volume":"72","author":"Alavi","year":"1970;","journal-title":"Ann Intern Med"},{"issue":"(5):","key":"key20250711060345_B31","doi-asserted-by":"crossref","first-page":"94\u2013","DOI":"10.3810\/pgm.2009.09.2056","article-title":"The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.","volume":"121","author":"Pi-Sunyer","year":"2009;","journal-title":"Postgrad Med"},{"issue":"(3):","key":"key20250711060345_B32","doi-asserted-by":"crossref","first-page":"1502\u2013","DOI":"10.1093\/rheumatology\/keaa289","article-title":"Long-term systemic glucocorticoid therapy and weight gain: a population-based cohort study.","volume":"60","author":"Fardet","year":"2021;","journal-title":"Rheumatology"},{"issue":"(5):","key":"key20250711060345_B33","doi-asserted-by":"crossref","first-page":"746\u2013","DOI":"10.1002\/art.23561","article-title":"Effects of glucocorticoids on weight change during the treatment of Wegener\u2019s granulomatosis.","volume":"59","author":"Wung","year":"2008;","journal-title":"Arthritis Rheum"},{"key":"key20250711060345_B34","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1186\/1471-2466-8-1","article-title":"Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease.","volume":"8:","author":"Schuetz","year":"2008;","journal-title":"BMC Pulm Med"},{"issue":"(2):","key":"key20250711060345_B35","doi-asserted-by":"crossref","first-page":"R77\u2013","DOI":"10.1530\/JOE-16-0118","article-title":"Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis.","volume":"230","author":"Diz-Chaves","year":"2016;","journal-title":"J Endocrinol"},{"key":"key20250711060345_B36","first-page":"111\u2013","article-title":"Prednisolone induced iatrogenic Cushing\u2019s syndrome associated with secondary diabetes: a case report.","volume":"9:","author":"Sateesh Kumar Reddy","year":"2018;","journal-title":"J Basic Clin Pharma"},{"key":"key20250711060345_B37","volume-title":"Glucocorticoid Therapy and Adrenal Suppression.","author":"Nicolaides","year":"2000."},{"key":"key20250711060345_B38","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.72019","article-title":"Side effects of glucocorticoids.","volume-title":"Pharmacokinetics and Adverse Effects of Drugs: Mechanisms and Risks Factors.","author":"Alan","year":"2018."},{"key":"key20250711060345_B39","first-page":"4\u2013","article-title":"Exogenous Cushing\u2019s syndrome secondary to intermittent high dose oral prednisone for presumed asthma exacerbations in the setting of multiple emergency department visits.","volume":"6:","author":"Manubolu","year":"2017;","journal-title":"J Clin Transl Endocrinol"},{"issue":"(4):","key":"key20250711060345_B40","doi-asserted-by":"crossref","first-page":"604\u2013","DOI":"10.1016\/j.jaad.2007.04.018","article-title":"Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study.","volume":"57","author":"Fardet","year":"2007;","journal-title":"J Am Acad Dermatol"},{"issue":"(7):","key":"key20250711060345_B41","doi-asserted-by":"crossref","first-page":"1119\u2013","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects.","volume":"68","author":"Huscher","year":"2009;","journal-title":"Ann Rheum Dis"},{"issue":"(1):","key":"key20250711060345_B42","doi-asserted-by":"crossref","first-page":"14220.","DOI":"10.1038\/s41598-017-14631-2","article-title":"Impact of hypertension versus diabetes on cardiovascular and all-cause mortality in Iranian older adults: results of 14 years of follow-up.","volume":"7","author":"Zafari","year":"2017;","journal-title":"Sci Rep"},{"issue":"(7):","key":"key20250711060345_B43","doi-asserted-by":"crossref","first-page":"1059\u2013","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension.","volume":"27","author":"Goodwin","year":"2012;","journal-title":"Pediatr Nephrol"},{"issue":"(1):","key":"key20250711060345_B44","doi-asserted-by":"crossref","first-page":"132\u2013","DOI":"10.1093\/rheumatology\/keaa209","article-title":"Glucocorticoid use is associated with an increased risk of hypertension.","volume":"60","author":"Costello","year":"2021;","journal-title":"Rheumatology"},{"issue":"(7):","key":"key20250711060345_B45","doi-asserted-by":"crossref","first-page":"1251\u2013","DOI":"10.1681\/ASN.2008040410","article-title":"Glucocorticoid-mediated hypertension: does the vascular smooth muscle hold all the answers?.","volume":"19","author":"Baum","year":"2008;","journal-title":"J Am Soc Nephrol"},{"key":"key20250711060345_B46","doi-asserted-by":"crossref","first-page":"333\u2013","DOI":"10.2147\/DMSO.S115855","article-title":"Diabetes and dyslipidemia: characterizing lipoprotein metabolism.","volume":"28:","author":"Tomkin","year":"2017;","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"(5):","key":"key20250711060345_B47","doi-asserted-by":"crossref","first-page":"604\u2013","DOI":"10.1016\/j.semarthrit.2015.10.010","article-title":"Dyslipidemia in systemic lupus erythematosus: just another comorbidity.","volume":"45","author":"Tselios","year":"2016;","journal-title":"Semin Arthritis Rheum"},{"key":"key20250711060345_B48","doi-asserted-by":"crossref","first-page":"41\u2013","DOI":"10.2147\/OARRR.S245662","article-title":"Correlation between steroid therapy and lipid profile in systemic lupus erythematosus patients.","volume":"12:","author":"Atik","year":"2020;","journal-title":"Open Access Rheumatol"},{"issue":"(1):","key":"key20250711060345_B49","doi-asserted-by":"crossref","first-page":"34\u2013","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_37_17","article-title":"Diabetes as \u201ccoronary artery disease risk equivalent\u201d: a historical perspective.","volume":"18","author":"Hajar","year":"2017;","journal-title":"Heart Views"},{"issue":"(4):","key":"key20250711060345_B50","doi-asserted-by":"crossref","first-page":"229\u2013","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.","volume":"339","author":"Haffner","year":"1998;","journal-title":"N Engl J Med"},{"key":"key20250711060345_B51","doi-asserted-by":"crossref","first-page":"33\u2013","DOI":"10.1159\/000360556","article-title":"Cardiovascular and metabolic impact of glucocorticoid replacement therapy.","volume":"43:","author":"Johannsson","year":"2014;","journal-title":"Front Horm Res"},{"issue":"(12):","key":"key20250711060345_B52","doi-asserted-by":"crossref","first-page":"e1003432.","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population\u2013based cohort study.","volume":"17","author":"Pujades-Rodriguez","year":"2020;","journal-title":"PLoS Med"},{"issue":"(8):","key":"key20250711060345_B53","doi-asserted-by":"crossref","first-page":"859\u2013","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.","volume":"90","author":"Souverein","year":"2004;","journal-title":"Heart"},{"key":"key20250711060345_B54","doi-asserted-by":"crossref","first-page":"603247.","DOI":"10.3389\/fphys.2020.603247","article-title":"The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy.","volume":"11:","author":"Gopal","year":"2020;","journal-title":"Front Physiol"},{"issue":"(4):","key":"key20250711060345_B55","doi-asserted-by":"crossref","first-page":"401\u2013","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction.","volume":"10","author":"Oktay","year":"2013;","journal-title":"Curr Heart Fail Rep"},{"issue":"(11):","key":"key20250711060345_B56","doi-asserted-by":"crossref","first-page":"2458.","DOI":"10.1007\/s00125-021-05522-3","article-title":"Diabetes and the risk of hospitalisation for infection: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"64","author":"Fang","year":"2021;","journal-title":"Diabetologia"},{"key":"key20250711060345_B57","doi-asserted-by":"crossref","first-page":"309\u2013","DOI":"10.1146\/annurev.immunol.18.1.309","article-title":"Glucocorticoids in T cell development and function.","volume":"18:","author":"Ashwell","year":"2000;","journal-title":"Annu Rev Immunol"},{"key":"key20250711060345_B58","article-title":"Corticosteroid Adverse Effects.","author":"Yasir","year":"2024."},{"issue":"(1):","key":"key20250711060345_B59","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.","volume":"8","author":"McGovern","year":"2020;","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"(1):","key":"key20250711060345_B60","first-page":"1\u2013","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.","volume":"9","author":"Liu","year":"2013;","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"(3):","key":"key20250711060345_B61","doi-asserted-by":"crossref","first-page":"410\u2013","DOI":"10.1016\/j.amjsurg.2012.11.018","article-title":"Corticosteroids and wound healing: Clinical considerations in the perioperative period.","volume":"206","author":"Wang","year":"2013;","journal-title":"Am J Surg"},{"key":"key20250711060345_B62","unstructured":"Prednesol 5 mg Tablets - Summary Product characteristics. Available from https:\/\/www.medicines.org.uk\/emc\/product\/14675\/smpc Accessed on 09 Feb 2024."},{"issue":"(2):","key":"key20250711060345_B63","doi-asserted-by":"crossref","first-page":"156\u2013","DOI":"10.1016\/j.clindermatol.2016.10.007","article-title":"Drug-induced acne.","volume":"35","author":"Kazandjieva","year":"2017;","journal-title":"Clin Dermatol"},{"key":"key20250711060345_B64","doi-asserted-by":"crossref","first-page":"681232.","DOI":"10.3389\/fmed.2021.681232","article-title":"Prevalence of sarcopenia and its association with diabetes: a meta-analysis of community-dwelling Asian population.","volume":"8:","author":"Chung","year":"2021;","journal-title":"Front Med (Lausanne)"},{"key":"key20250711060345_B65","doi-asserted-by":"crossref","first-page":"27\u2013","DOI":"10.1016\/j.exger.2015.06.002","article-title":"The role of muscle mass and body fat on disability among older adults: a cross-national analysis.","volume":"69:","author":"Tyrovolas","year":"2015;","journal-title":"Exp Gerontol"},{"issue":"(10):","key":"key20250711060345_B66","doi-asserted-by":"crossref","first-page":"1148\u2013","DOI":"10.1007\/s12603-018-1139-9","article-title":"International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management.","volume":"22","author":"Dent","year":"2018;","journal-title":"J Nutr Health Aging"},{"issue":"(6):","key":"key20250711060345_B67","first-page":"830\u2013","article-title":"Diabetes Care in India.","volume":"81","author":"Joshi","year":"2015;","journal-title":"Ann Glob Health"},{"issue":"(10):","key":"key20250711060345_B68","doi-asserted-by":"crossref","first-page":"3621\u2013","DOI":"10.1210\/jc.2017-00042","article-title":"Type 2 diabetes and osteoporosis: a guide to optimal management.","volume":"102","author":"Paschou","year":"2017;","journal-title":"J Clin Endocrinol Metab"},{"issue":"(12):","key":"key20250711060345_B69","doi-asserted-by":"crossref","first-page":"1480\u2013","DOI":"10.1016\/j.metabol.2014.09.002","article-title":"Type 2 diabetes mellitus and fracture risk.","volume":"63","author":"Dede","year":"2014;","journal-title":"Metabolism"},{"issue":"(5):","key":"key20250711060345_B70","doi-asserted-by":"crossref","first-page":"734\u2013","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice.","volume":"44","author":"Kanis","year":"2009;","journal-title":"Bone"},{"key":"key20250711060345_B71","article-title":"An Overview of Glucocorticoid-induced Osteoporosis.","author":"Ilias","year":"2000."},{"key":"key20250711060345_B72","doi-asserted-by":"crossref","first-page":"777\u2013","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.","volume":"13:","author":"van Staa","year":"2002;","journal-title":"Osteoporos Int"},{"issue":"(22):","key":"key20250711060345_B73","doi-asserted-by":"crossref","first-page":"15219.","DOI":"10.3390\/ijerph192215219","article-title":"Does diabetes mellitus increase the risk of avascular osteonecrosis? A systematic review and meta-analysis.","volume":"19","author":"Konarski","year":"2022;","journal-title":"Int J Environ Res Public Health"},{"issue":"(11):","key":"key20250711060345_B74","doi-asserted-by":"crossref","first-page":"721\u2013","DOI":"10.1016\/j.autrev.2010.06.007","article-title":"Steroid induced osteonecrosis: an analysis of steroid dosing risk.","volume":"9","author":"Powell","year":"2010;","journal-title":"Autoimmun Rev"},{"issue":"(9):","key":"key20250711060345_B75","doi-asserted-by":"crossref","first-page":"633\u2013","DOI":"10.1038\/sj.sc.3100647","article-title":"Risk of avascular necrosis following short term megadose methylprednisolone treatment.","volume":"36","author":"Wing","year":"1998;","journal-title":"Spinal Cord"},{"issue":"(1):","key":"key20250711060345_B76","doi-asserted-by":"crossref","first-page":"39\u2013","DOI":"10.2337\/dc18-1258","article-title":"Real-world database examining the association between avascular necrosis of the femoral head and diabetes in Taiwan.","volume":"42","author":"Lai","year":"2019;","journal-title":"Diabetes Care"},{"issue":"(3):","key":"key20250711060345_B77","doi-asserted-by":"crossref","first-page":"172\u2013","DOI":"10.1002\/dmrr.1075","article-title":"Diabetic cataracts: mechanisms and management.","volume":"26","author":"Obrosova","year":"2010;","journal-title":"Diabetes Metab Res Rev"},{"issue":"(4):","key":"key20250711060345_B78","doi-asserted-by":"crossref","first-page":"652\u2013","DOI":"10.1016\/j.ophtha.2008.12.001","article-title":"Use of inhaled and oral corticosteroids and the long-term risk of cataract.","volume":"116","author":"Wang","year":"2009;","journal-title":"Ophthalmology"},{"issue":"(6):","key":"key20250711060345_B79","doi-asserted-by":"crossref","first-page":"605\u2013","DOI":"10.1111\/j.1442-9071.2010.02341.x","article-title":"Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial.","volume":"38","author":"Gillies","year":"2010;","journal-title":"Clin Exp Ophthalmol"},{"issue":"(1):","key":"key20250711060345_B80","doi-asserted-by":"crossref","first-page":"349.","DOI":"10.1186\/s12886-021-02114-y","article-title":"The elevated risk of sight-threatening cataract in diabetes with retinopathy: a retrospective population-based cohort study.","volume":"21","author":"Nien","year":"2021;","journal-title":"BMC Ophthalmol"},{"issue":"(9):","key":"key20250711060345_B81","first-page":"1430\u2013","article-title":"Diabetes and risk of glaucoma: systematic review and a meta-analysis of prospective cohort studies.","volume":"10","author":"Zhao","year":"2017;","journal-title":"Int J Ophthalmol"},{"issue":"(2):","key":"key20250711060345_B82","first-page":"67\u2013","article-title":"Steroid-induced glaucoma: an avoidable irreversible blindness.","volume":"11","author":"Phulke","year":"2017;","journal-title":"J Curr Glaucoma Pract"},{"issue":"(6):","key":"key20250711060345_B83","doi-asserted-by":"crossref","first-page":"979\u2013","DOI":"10.2337\/diacare.24.6.979","article-title":"Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes.","volume":"24","author":"Harris","year":"2001;","journal-title":"Diabetes Care"},{"issue":"(Suppl 1):","key":"key20250711060345_B84","first-page":"S1\u2013","article-title":"Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada.","volume":"37","year":"2013;","journal-title":"Can J Diabetes"},{"issue":"(2):","key":"key20250711060345_B85","doi-asserted-by":"crossref","first-page":"117\u2013","DOI":"10.5535\/arm.2020.44.2.117","article-title":"Changes in blood glucose level after steroid injection for musculoskeletal pain in patients with diabetes.","volume":"44","author":"Shin","year":"2020;","journal-title":"Ann Rehabil Med"},{"key":"key20250711060345_B86","article-title":"Continuous glucose monitoring of steroid-induced hyperglycemia in patients with dermatologic diseases.","author":"Kleinhans","year":"2023","journal-title":"J Diabetes Sci Technol"},{"issue":"(Suppl 1):","key":"key20250711060345_B87","first-page":"S83\u2013","article-title":"6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.","volume":"45","year":"2022;","journal-title":"Diabetes Care"},{"issue":"(2):","key":"key20250711060345_B88","first-page":"237\u2013","article-title":"Expert Consensus Recommendations on time in range for monitoring glucose levels in people with diabetes: an Indian perspective.","volume":"14","author":"Mohan","year":"2023;","journal-title":"Diabetes Ther"},{"key":"key20250711060345_B89","article-title":"Basic and Clinical Pharmacology, 12th Edition.","author":"Katzung","year":"2012."},{"key":"key20250711060345_B90","first-page":"289.","article-title":"Essentials of Medical Pharmacology, 7th Edition.","author":"Tripathi","year":"2013"},{"issue":"(1):","key":"key20250711060345_B91","doi-asserted-by":"crossref","first-page":"9\u2013","DOI":"10.1016\/j.japh.2023.10.010","article-title":"Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: a systematic review and meta-analysis.","volume":"64","author":"Al-Hindi","year":"2024;","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"(2):","key":"key20250711060345_B92","doi-asserted-by":"crossref","first-page":"156\u2013","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss.","volume":"8","author":"Yerevanian","year":"2019;","journal-title":"Curr Obes Rep"},{"issue":"(1):","key":"key20250711060345_B93","doi-asserted-by":"crossref","first-page":"44\u2013","DOI":"10.1007\/s12325-018-0824-8","article-title":"Body weight considerations in the management of type 2 diabetes.","volume":"36","author":"Apovian","year":"2019;","journal-title":"Adv Ther"},{"key":"key20250711060345_B94","doi-asserted-by":"crossref","first-page":"30.","DOI":"10.1186\/s13098-018-0331-8","article-title":"Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial.","volume":"10:","author":"Leiter","year":"2018;","journal-title":"Diabetol Metab Syndr"},{"issue":"(3):","key":"key20250711060345_B95","doi-asserted-by":"crossref","first-page":"e061807.","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.","volume":"13","author":"Ma","year":"2023;","journal-title":"BMJ Open"},{"key":"key20250711060345_B96","doi-asserted-by":"crossref","first-page":"105108.","DOI":"10.1016\/j.phrs.2020.105108","article-title":"Antidiabetic drugs and blood pressure changes.","volume":"161:","author":"Ilias","year":"2020;","journal-title":"Pharmacol Res"},{"issue":"(2):","key":"key20250711060345_B97","doi-asserted-by":"crossref","first-page":"133\u2013","DOI":"10.1111\/j.1462-8902.2004.00325.x","article-title":"The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.","volume":"6","author":"Buse","year":"2004;","journal-title":"Diabetes Obes Metab"},{"key":"key20250711060345_B98","first-page":"103633.","article-title":"Effects of novel glucose-lowering drugs on the lipid parameters: a systematic review and meta-analysis.","volume":"77:","author":"Dar","year":"2022;","journal-title":"Ann Med Surg (Lond)"},{"issue":"(2):","key":"key20250711060345_B99","doi-asserted-by":"crossref","first-page":"65\u2013","DOI":"10.1007\/s12471-021-01579-2","article-title":"The effects of antidiabetic agents on heart failure.","volume":"30","author":"Wijnen","year":"2022;","journal-title":"Neth Heart J"},{"key":"key20250711060345_B100","doi-asserted-by":"crossref","first-page":"735824.","DOI":"10.3389\/fendo.2021.735824","article-title":"Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis.","volume":"12:","author":"Zhang","year":"2021;","journal-title":"Front Endocrinol"},{"issue":"(4):","key":"key20250711060345_B101","doi-asserted-by":"crossref","first-page":"895\u2013","DOI":"10.3803\/EnM.2021.1026","article-title":"Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus.","volume":"36","author":"Ha","year":"2021;","journal-title":"Endocrinol Metab"},{"key":"key20250711060345_B102","doi-asserted-by":"crossref","first-page":"697442.","DOI":"10.3389\/fphar.2021.697442","article-title":"The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment.","volume":"12:","author":"Xie","year":"2021;","journal-title":"Front Pharmacol"},{"issue":"(1):","key":"key20250711060345_B103","first-page":"1\u2013","article-title":"RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.","volume":"24","author":"Chawla","year":"2020;","journal-title":"Indian J Endocrinol Metab"},{"issue":"(1):","key":"key20250711060345_B104","doi-asserted-by":"crossref","first-page":"89\u2013","DOI":"10.2169\/internalmedicine.52.8622","article-title":"Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.","volume":"52","author":"Matsuo","year":"2013;","journal-title":"Intern Med"},{"issue":"(4):","key":"key20250711060345_B105","doi-asserted-by":"crossref","first-page":"259\u2013","DOI":"10.1097\/MPH.0b013e3181978fd4","article-title":"Fitness of children with standard-risk acute lymphoblastic leukemia during maintenance therapy: response to a home-based exercise and nutrition program.","volume":"31","author":"Moyer-Mileur","year":"2009;","journal-title":"J Pediatr Hematol Oncol"},{"issue":"(6):","key":"key20250711060345_B106","doi-asserted-by":"crossref","first-page":"649\u2013","DOI":"10.1177\/0961203312436854","article-title":"Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids.","volume":"21","author":"Davies","year":"2012;","journal-title":"Lupus"},{"issue":"(4):","key":"key20250711060345_B107","doi-asserted-by":"crossref","first-page":"e12312.","DOI":"10.1111\/cob.12312","article-title":"Obesity prevention in corticosteroid-treated patients: Use and effectiveness of strategies for weight management.","volume":"9","author":"Conklin","year":"2019;","journal-title":"Clin Obes"},{"key":"key20250711060345_B108","doi-asserted-by":"crossref","first-page":"105782.","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes.","volume":"171:","author":"Lazzaroni","year":"2021;","journal-title":"Pharmacol Res"},{"key":"key20250711060345_B109","doi-asserted-by":"crossref","first-page":"189.","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","volume":"20:","author":"Giugliano","year":"2021;","journal-title":"Cardiovasc Diabetol"},{"issue":"(1):","key":"key20250711060345_B110","first-page":"1\u2013","article-title":"Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.","volume":"21","author":"Davies","year":"2022;","journal-title":"Cardiovasc Diabetol"},{"issue":"(3):","key":"key20250711060345_B111","first-page":"195\u2013","article-title":"Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.","volume":"19","author":"Papagianni","year":"2015;","journal-title":"Hippokratia"},{"issue":"(1):","key":"key20250711060345_B112","doi-asserted-by":"crossref","first-page":"10\u2013","DOI":"10.1016\/j.jcjd.2021.04.006","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis.","volume":"46","author":"Colacci","year":"2022;","journal-title":"Can J Diabetes"},{"issue":"(4):","key":"key20250711060345_B113","first-page":"331\u2013","article-title":"Diabetic ketoacidosis in a patient with type 2 diabetes on canagliflozin and dexamethasone.","volume":"3","author":"Alexander","year":"2017;","journal-title":"AACE Clin Case Rep"},{"issue":"(36):","key":"key20250711060345_B114","doi-asserted-by":"crossref","first-page":"3599\u2013","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021;","journal-title":"Eur Heart J"},{"issue":"(18):","key":"key20250711060345_B115","first-page":"e895\u2013","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022;","journal-title":"Circulation"},{"key":"key20250711060345_B116","doi-asserted-by":"crossref","first-page":"403\u2013","DOI":"10.1007\/978-3-319-18449-4_82","volume-title":"Steroid acne. Inpatient Dermatology.","author":"Choi","year":"2018"},{"key":"key20250711060345_B117","doi-asserted-by":"crossref","first-page":"7985728.","DOI":"10.1155\/2017\/7985728","article-title":"Protein intake, especially vegetable protein intake, is associated with higher skeletal muscle mass in elderly patients with type 2 diabetes.","volume":"2017:","author":"Miki","year":"2017;","journal-title":"J Diabetes Res"},{"issue":"(2):","key":"key20250711060345_B118","doi-asserted-by":"crossref","first-page":"250\u2013","DOI":"10.1093\/ajcn\/78.2.250","article-title":"Essential amino acids are primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy elderly adults.","volume":"78","author":"Volpi","year":"2003;","journal-title":"Am J Clin Nutr"},{"issue":"(6):","key":"key20250711060345_B119","doi-asserted-by":"crossref","first-page":"3091\u2013","DOI":"10.1016\/j.dsx.2019.11.009","article-title":"Dietary proteins, metabolic syndrome, and sarcopenia: focus on Asian Indians.","volume":"13","author":"Gulati","year":"2019;","journal-title":"Diabetes Metab Syndr"},{"issue":"(5):","key":"key20250711060345_B120","doi-asserted-by":"crossref","first-page":"1963\u2013","DOI":"10.1210\/jc.2015-4180","article-title":"Does sitagliptin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study.","volume":"101","author":"Majumdar","year":"2016;","journal-title":"J Clin Endocrinol Metab"},{"key":"key20250711060345_B121","doi-asserted-by":"crossref","first-page":"107990.","DOI":"10.1016\/j.diabres.2019.107990","article-title":"Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"159:","author":"Zhang","year":"2020;","journal-title":"Diabetes Res Clin Pract"},{"key":"key20250711060345_B122","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1038603","article-title":"Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies.","volume":"13","author":"Wang","year":"2023;","journal-title":"Front Endocrinol"},{"key":"key20250711060345_B123","article-title":"Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.","volume":"6","author":"Fu","year":"2016;","journal-title":"Sci Rep"},{"issue":"(20):","key":"key20250711060345_B124","doi-asserted-by":"crossref","first-page":"580\u2013","DOI":"10.21037\/atm.2019.09.51","article-title":"Effect of type 2 diabetes medications on fracture risk.","volume":"7","author":"Guja","year":"2019;","journal-title":"Ann Transl Med"},{"issue":"(12):","key":"key20250711060345_B125","doi-asserted-by":"crossref","first-page":"1199\u2013","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.","volume":"18","author":"Tang","year":"2016;","journal-title":"Diabetes Obes Metab"},{"key":"key20250711060345_B126","first-page":"51\u2013","article-title":"Characteristics and management of steroid-induced glaucoma.","author":"Horan"},{"issue":"(8):","key":"key20250711060345_B127","doi-asserted-by":"crossref","first-page":"718\u2013","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology.","volume":"61","author":"Buttgereit","year":"2002;","journal-title":"Ann Rheum Dis"},{"issue":"(1):","key":"key20250711060345_B128","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.","volume":"18","author":"Parente","year":"2017;","journal-title":"BMC Pharmacol Toxicol"},{"key":"key20250711060345_B129","unstructured":"Farinde A, Talavera F. Corticosteroid Dose Equivalents. Updated: Apr 18, 2019. Available from https:\/\/emedicine.medscape.com\/article\/2172042-overview Accessed 18 July 2023"},{"key":"key20250711060345_B130","unstructured":"Emflaza highlights of Prescribing information https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208684"},{"key":"key20250711060345_B131","unstructured":"Calcort 6mg Tablets. SMPC. Last updated on EMC: 13 Apr 2023 https:\/\/www.medicines.org.uk\/emc\/product\/13999\/smpc#gref"},{"key":"key20250711060345_B132","unstructured":"List of drugs during 2004. Available at https:\/\/cdscoonline.gov.in\/CDSCO\/"},{"issue":"(6):","key":"key20250711060345_B133","doi-asserted-by":"crossref","first-page":"890\u2013","DOI":"10.1177\/0961203317751854","article-title":"Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.","volume":"27","author":"Ganapati","year":"2018;","journal-title":"Lupus"},{"issue":"(2):","key":"key20250711060345_B134","first-page":"e510.","article-title":"Deflazacort versus prednisolone: randomized controlled trial in treatment of children with idiopathic nephrotic syndrome.","volume":"25","author":"Singhal","year":"2015;","journal-title":"Iran J Pediatr"},{"issue":"(11):","key":"key20250711060345_B135","first-page":"3795\u2013","article-title":"Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients.","volume":"83","author":"Lippuner","year":"1998;","journal-title":"J Clin Endocrinol Metab"},{"issue":"(3):","key":"key20250711060345_B136","doi-asserted-by":"crossref","first-page":"197\u2013","DOI":"10.1111\/j.1432-2277.1997.tb00685.x","article-title":"Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: a prospective trial in renal transplants.","volume":"10","author":"Kim","year":"1997;","journal-title":"Transplant Int"},{"issue":"(4):","key":"key20250711060345_B137","doi-asserted-by":"crossref","first-page":"679\u2013","DOI":"10.1001\/archinte.1987.00370040061011","article-title":"Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics.","volume":"147","author":"Bruno","year":"1987;","journal-title":"Arch Intern Med"},{"issue":"(5):","key":"key20250711060345_B138","doi-asserted-by":"crossref","first-page":"734\u2013","DOI":"10.1007\/s00467-006-0403-0","article-title":"Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients.","volume":"22","author":"Ferraris","year":"2007;","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T06:04:11Z","timestamp":1752213851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-7-79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":138,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.59556\/japi.72.0573"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0573","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}